The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...

Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its ...

Merck & Co (NYSE:MRK)., the second-largest U.S. drugmaker by revenue, is facing a jury trial over accusations that it ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

Robert F. Kennedy Jr. plans to continue earning from legal cases while heading the Department of Health and Human Services, ...

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The first week of President Donald Trump’s second term included several executive orders and actions that will be detrimental ...

Robert F. Kennedy Jr. is set to appear before the Senate Finance Committee for the first of two confirmation hearings as ...

The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.